Cell / tissue culture

Gene therapy
#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Immunology #Lead discovery #Molecular medicine #Oncology #Preclinical #Regenerative Medicine #Regulatory #Stem cells #Therapeutics #Toxicology #Translational #Translational chemistry

Cell Therapy & Gene Therapy – The emerging fourth pillar of healthcare systems

Cell Therapy & Gene Therapy - The emerging fourth pillar of healthcare systems By Keith Thompson As the CEO of an organisation that deals exclusively in cell therapy and gene therapy, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Clinical trials #Combinatorial chemistry #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #In Silico Biology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Medicinal chemistry #Metabolomics #Microbiome #Molecular medicine #Oncology #Patent Law #PCR #Pharmacogenomics #Pharmacokinetics / Pharmacodynamics #Pharmacology #Pharmokinetics #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry #Urinary

Reigniting Pharmaceutical Innovation Through Holistic Drug Targeting

By Dr A Roy, Prof B Patwardhan and Dr R Chaguturu Modern drug discovery approaches take too long, are too expensive, have too many clinical failures and uncertain outcomes. There are many reasons for this unsustainable business model, but primarily, the approaches are not comprehensively holistic. Secondly, none of the… Read More

#Archive

High content screening
#AI / data analytics / healthtech / informatics #Analysis #Analytical chemistry #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Molecular medicine #Pharmokinetics #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Toxicology #Translational #Translational chemistry

Latest Developments in High Content Screening Systems

By Dr John Comley High-content screening (HCS) is a well-established approach for the multiparametric analysis of cellular events. Since its first introduction more than a decade ago, high content imaging systems have continually evolved with many improvements enabled to meet user demands of greater flexibility and the growing requirements of… Read More

#Archive

#AI / data analytics / healthtech / informatics #Animal models #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical trials #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Oncology #Preclinical #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Ex Vivo vs In Vivo – The challenge of generating meaningful results with traditional cell culture

By Dr James Lim and Dr Fred Aswad While the use of human cell lines has become a permanent fixture in drug discovery and development, the lingering issue has been in their inconsistent results. This article discusses current attempts to make results from cell culture systems more biologically relevant which,… Read More

#Archive

#Academic #ADME / Tox #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Clinical specialities #Drug development #Drug discovery #Enabling technologies #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Lead discovery #Metabolomics #Organic chemistry #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

Microtissues For In Vitro Toxicity Assessment: Cost effective and in vivo relevant toxicology tools

Microtissues For In Vitro Toxicity Assessment: Cost effective and in vivo relevant toxicology tools By Dr Stephanie Ravenscroft, Dr Caroline Bauch, Dr Laura Hinton and Dr Paul Walker Conventional two-dimensional (2D) cell models (adherent cells grown on cell culture plates or cells in suspension) are limited in their abilities to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Business #Cell / tissue culture #Cell culture #Cellular assays #Drug development #Drug discovery #Enabling technologies #Gene editing #Genomics #High Content Screening #High throughput screening #Imaging #Microfluidics #Molecular medicine #Oncology #Preclinical #RNA #Screening #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Preclinical Imaging: Improving Translational Power In Oncology

Preclinical Imaging: Improving Translational Power In Oncology By Dr Todd Sasser Imaging has long been indispensable in clinical practice, and researchers have for many years used the same toolbox of imaging modalities as a component of their preclinical and drug development work. Imaging continues to provide crucial datasets to scientists… Read More

#Archive

Stem cells
#AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biobanking #Biochemistry #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Enabling technologies #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Immunology #Lead discovery #Molecular medicine #Pharmacology #Precision medicine #Preclinical #Protein chemistry / Proteomics #Regenerative Medicine #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology

The stem cell dilemma: Reprogramming in-house versus off-the-shelf

  by Dr John Comley The case for using more physiologically-relevant cells for modelling disease pathophysiology, for understanding a drug’s mechanism of action, in toxicology/safety testing and in phenotypic drug screening assays is now well accepted. Human induced pluripotent stem cells (iPSCs) are seen as a resource from which to… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development optimisation & technology #Automation / robotics #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Chemical engineering #Chemistry #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Immunology / Virology & Vaccines #Lead discovery #Oncology #Regulatory #RNA #Stem cells #System biology #Systems biology #Therapeutics #Toxicology

Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype

Chimeric Antigen Receptor T-cells (CAR-T): Looking beyond the hype By Christoph Oldenburg, Dr Markus Thunecke and Dr John Herrmann While Chimeric Antigen Receptor T-cells (CAR-T), have already demonstrated convincing efficacy in a specific setting, the jury is still out on whether they are a ‘game-changer’ for oncology as a whole… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Animal models #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical trials #Computational chemistry #Drug development #Drug discovery #Drug repositioning #Drug targets #Gene therapy #High Content Screening #Immunology #Immunology / Virology & Vaccines #Mass spectrometry / NMR #Molecular medicine #Oncology #Pathology #Preclinical #Regulatory #RNA #Stem cells #Therapeutics

Using Syngeneic Models for the Discovery of Combination Therapy Targets & Predictive Biomarkers of Immunotherapy Efficacy

By Dr Jean- Pierre Wery Optimal treatment for any disease is one that can cure or prevent spreading with minimal impact on the patient’s quality of life. In the case of cancer, therapeutic agents were initially designed to kill rapidly dividing cells. These traditional treatments, namely chemotherapy and radiotherapy, remain… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical trials #Combinatorial chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Oncology #Pathology #PCR #Pharmacology #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Phenotypic Drug Discovery: Striving towards high level biological relevance

Phenotypic Drug Discovery: Striving towards the highest level of biological relevance By Dr John Comley Phenotypic drug discovery (PDD) implies screening where the molecular mechanism of action is not assumed and does not require knowledge of the molecular target. As such phenotypic drug discovery is comparable to empirical screening, which… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Chemistry #Clinical specialities #Drug development #Drug discovery #Drug targets #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Medicinal chemistry #Molecular medicine #Patent Law #PCR #Protein chemistry / Proteomics #Regenerative Medicine #Regulatory #RNA #Screening #Stem cells #System biology #Systems biology #Target validation #Therapeutics

The California Institute for Regenerative Medicines Human iPSC Initiative

The California Institute for Regenerative Medicines Human iPSC Initiative By Dr Thomas J. Novak This article discusses large-scale generation of patient-derived induced pluripotent stem cells (iPSCs) to accelerate the understanding of disease biology and drug discovery. In 2012, the California Institute for Regenerative Medicine (CIRM) announced its Human iPSC Initiative,… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Chemical engineering #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene editing #Gene therapy #Genetics / genomes #Genomics #High Content Screening #High throughput screening #Imaging #Immunology #In Silico Biology #Metabolomics #Oncology #PCR #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Translational #Translational chemistry

New Developments in Single Cell Separation and Analysis Technologies

New Developments in Single Cell Separation and Analysis Technologies By Dr John Comley Drug Discovery Recent advances of single cell technologies are facilitating the opportunity to discern biological insights within individual cells and providing a means to reveal previously hidden relationships between individual cells within a population. Single cell technologies… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development & optimisation #Assay development optimisation & technology #Biochemistry #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Drug development #Drug discovery #Drug repositioning #Drug targets #Enabling technologies #Gene therapy #Genetics / genomes #Genetics / genomics #Genomics #High Content Screening #High throughput screening #Lead discovery #Lead optimisation #Metabolomics #Molecular medicine #Oncology #Pathology #Pharmacogenomics #Precision medicine #Protein chemistry / Proteomics #RNA #Screening #Sequencing #Stem cells #System biology #Systems biology #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Individualised Systems Medicine: Next-Generation Precision Cancer Medicine and Drug Positioning

Individualised Systems Medicine: Next-Generation Precision Cancer Medicine and Drug Positioning By Tea Pemovska, Paaivi Östling, Caroline Heckman, Olli Kallioniemi and Krister Wennerberg A growing number of oncology drugs are currently clinically available and more than a thousand compounds are being developed for oncology indications. Thus, the challenge is to systematically… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Analysis #Animal models #Antimicrobials #Assay development optimisation & technology #Automation / robotics #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene therapy #Immunology #Immunology / Virology & Vaccines #Lead discovery #Microbiology #Microbiome #Molecular medicine #Oncology #PCR #Pharmokinetics #Preclinical #Protein chemistry / Proteomics #RNA #Stem cells #System biology #Systems biology #Therapeutics #Translational #Translational chemistry

Anti-Infective Immunotherapy For Treating Hospital Acquired Infections

Anti-Infective Immunotherapy For Treating Hospital Acquired Infections By Dr Vu Truong, Dr Nadine Weich, Dr Andreas Loos and Dr Eric Patzer The frequency of nosocomial (acquired in healthcare facility) pneumonia has experienced a steady increase in recent years, and treatment of these infections has become more challenging and expensive due… Read More

#Archive

#Academic #AI / data analytics / healthtech / informatics #Assay development optimisation & technology #Automation / robotics #Biologics / Biotechnology #Biomarkers #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Clinical specialities #Clinical trials #Drug development #Drug discovery #Drug targets #Gene editing #Gene therapy #Genetics / genomes #High Content Screening #Immunology #Molecular medicine #Oncology #Preclinical #Protein chemistry / Proteomics #Regulatory #RNA #Stem cells #Target validation #Therapeutics #Toxicology #Translational #Translational chemistry

Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors

Adoptive T-Cell Therapies: unlocking the potential of engineered antigen receptors By Dr Cenk Sumen, Dr Dan Williams and Dr Gwendolyn Binder-Scholl T-cells with engineered receptors to target tumours represent living drugs with enormous potential in the fight against cancer, but many challenges remain to be overcome in order for their… Read More

#Archive

#AI / data analytics / healthtech / informatics #Analysis #Assay development optimisation & technology #Automation / robotics #Business #Cell / tissue culture #Cell culture #Cell therapy #Cellular & Molecular biology #Cellular assays #Computational chemistry #Drug development #Drug discovery #Drug targets #Enabling technologies #Flow Cytometry #Gene therapy #Genetics / genomes #High Content Screening #High throughput screening #Imaging #Immunology #Lead discovery #Lead optimisation #Mass spectrometry / NMR #Oncology #PCR #RNA #Screening #Stem cells #System biology #Systems biology

High Throughput Flow: A High Content Platform For Phenotypic Screening?

High Throughput Flow: A High Content Platform For Phenotypic Screening? Dr John Comley Flow cytometry has many of the technology attributes (eg multi-parameter analysis of cell suspensions) needed when attempting to profile a phenotypic drug response. However, for flow cytometry to be considered the phenotypic drug screening platform of choice… Read More

#Archive